Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 179 of the 179 references it cites were found in a registry or an index.

Schizophrenia and the α7 Nicotinic Acetylcholine Receptor

Martin, Laura F., Freedman, Robert · 2007 · International Review of Neurobiology

Abstract

In addition to the devastating symptoms of psychosis, many people with schizophrenia also suffer from cognitive impairment. These cognitive symptoms lead to marked dysfunction and can impact employability, treatment adherence, and social skills. Deficits in P50 auditory gating are associated with attentional impairment and may contribute to cognitive symptoms and perceptual disturbances. This nicotinic cholinergic-mediated inhibitory process represents a potential new target for therapeutic intervention in schizophrenia. This chapter will review evidence implicating the nicotinic cholinergic, and specifically, the alpha7 nicotinic receptor system in the pathology of schizophrenia. Impaired auditory sensory gating has been linked to the alpha7 nicotinic receptor gene on the chromosome 15q14 locus. A majority of persons with schizophrenia are heavy smokers. Although nicotine can acutely reverse diminished auditory sensory gating in people with schizophrenia, this effect is lost on a chronic basis due to receptor desensitization. The alpha7 nicotinic agonist 3-(2,4 dimethoxy)benzylidene-anabaseine (DMXBA) can also enhance auditory sensory gating in animal models. DMXBA is well tolerated in humans and a new study in persons with schizophrenia has found that DMXBA enhances both P50 auditory gating and cognition. alpha7 Nicotinic acetylcholine receptor agonists appear to be viable candidates for the treatment of cognitive disturbances in schizophrenia.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0074-7742(06)78008-4

Cites

179 of 179 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 179 references

Research works printed but not linked: 1

  1. Kem, 1996, Two primary GTS‐21 metabolites are potent partial agonists at alpha‐7 nicotinic receptors expressed in the Xenopus oocyte, Soc. Neurosci. Abstr., 22, 268

Cited by

See all 213

Metadata

Authors
Martin, L. F., & Freedman, R.
Affiliations
Denver VA Medical Center (US)
Venue
International Review of Neurobiology
Publisher
Elsevier
Published
2007
Volume
78
Pages
225-246
ISSN
0074-7742 (ISSN-L)
OpenAlex
W97382084
Cited by
213
References
179
Citations by year
2026: 3 · 2025: 3 · 2024: 3 · 2023: 6 · 2022: 7 · 2021: 10 · 2020: 4 · 2019: 5 · 2018: 6 · 2017: 9 · 2016: 16 · 2015: 15 · 2014: 13 · 2013: 20 · 2012: 22
FWCI
25.70
Type
book chapter
Language
en
Open access
closed
Locations
  • International review of neurobiology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords
schizophrenia, alpha7 nicotinic acetylcholine receptor, auditory gating, cognitive impairment, nicotine, receptor desensitization, nicotinic agonists, attentional impairment
MeSH terms
Acetylcholine, Animals, Brain, Cognition Disorders, Hallucinations, Humans, Receptors, Nicotinic, Schizophrenia, Nicotinic Agonists, Genetic Predisposition to Disease, Sensory Gating, alpha7 Nicotinic Acetylcholine Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Schizophrenia and the α7 Nicotinic Acetylcholine Receptor. https://app.cochat.ai/papers/10.1016/s0074-7742(06)78008-4
The paper
Martin, L. F., & Freedman, R. (2007). Schizophrenia and the α7 Nicotinic Acetylcholine Receptor. International Review of Neurobiology. https://doi.org/10.1016/s0074-7742(06)78008-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.